Principal Financial Group Inc Xencor Inc Transaction History

Principal Financial Group Inc

$172 Billion
Q4 2024

A detailed history of Principal Financial Group Inc transactions in Xencor Inc stock. As of the latest transaction made, Principal Financial Group Inc holds 340,145 shares of XNCR stock, worth $5.99 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

340,145

Holding current value

$5.99 Million

% of portfolio

0.0%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Jan 31, 2025	BUY	$19.43 - $26.84 $6.61 Million - $9.13 Million	340,145 New	340,145 $7.82 Million
Q3 2024 Oct 31, 2024	SELL	$15.7 - $21.65 $239,440 - $330,184	-15,251 Reduced 4.97%	291,916 $5.87 Million
Q2 2024 Jul 29, 2024	SELL	$18.21 - $24.5 $300,428 - $404,201	-16,498 Reduced 5.1%	307,167 $5.81 Million
Q1 2024 Apr 29, 2024	SELL	$18.65 - $26.52 $342,134 - $486,509	-18,345 Reduced 5.36%	323,665 $7.16 Million
Q4 2023 Feb 07, 2024	SELL	$16.53 - $21.42 $67,888 - $87,971	-4,107 Reduced 1.19%	342,010 $7.26 Million
Q3 2023 Nov 02, 2023	SELL	$20.08 - $25.39 $269,694 - $341,013	-13,431 Reduced 3.74%	346,117 $6.97 Million
Q2 2023 Aug 07, 2023	SELL	$24.77 - $29.9 $413,881 - $499,599	-16,709 Reduced 4.44%	359,548 $8.98 Million
Q1 2023 May 09, 2023	SELL	$25.95 - $36.95 $150,639 - $214,494	-5,805 Reduced 1.52%	376,257 $10.5 Million
Q4 2022 Feb 09, 2023	BUY	$24.79 - $30.86 $195,022 - $242,775	7,867 Added 2.1%	382,062 $9.95 Million
Q3 2022 Nov 09, 2022	BUY	$24.62 - $32.44 $10,758 - $14,176	437 Added 0.12%	374,195 $9.72 Million
Q2 2022 Aug 10, 2022	SELL	$19.74 - $29.01 $570,367 - $838,214	-28,894 Reduced 7.18%	373,758 $10.2 Million
Q1 2022 May 09, 2022	SELL	$26.68 - $41.63 $82,041 - $128,012	-3,075 Reduced 0.76%	402,652 $10.7 Million
Q4 2021 Feb 09, 2022	SELL	$33.67 - $43.44 $510,740 - $658,941	-15,169 Reduced 3.6%	405,727 $16.3 Million
Q3 2021 Nov 09, 2021	SELL	$30.65 - $35.68 $127,136 - $148,000	-4,148 Reduced 0.98%	420,896 $13.7 Million
Q2 2021 Aug 10, 2021	BUY	$34.33 - $44.68 $87,198 - $113,487	2,540 Added 0.6%	425,044 $14.7 Million
Q1 2021 May 10, 2021	BUY	$40.81 - $53.88 $80,558 - $106,359	1,974 Added 0.47%	422,504 $18.2 Million
Q4 2020 Feb 08, 2021	SELL	$36.63 - $47.63 $326,629 - $424,716	-8,917 Reduced 2.08%	420,530 $18.3 Million
Q3 2020 Nov 06, 2020	BUY	$30.09 - $43.02 $1.13 Million - $1.62 Million	37,612 Added 9.6%	429,447 $16.7 Million
Q2 2020 Aug 05, 2020	BUY	$27.76 - $33.42 $247,064 - $297,438	8,900 Added 2.32%	391,835 $12.7 Million
Q1 2020 May 12, 2020	SELL	$20.69 - $37.79 $442,310 - $807,874	-21,378 Reduced 5.29%	382,935 $11.4 Million
Q4 2019 Feb 05, 2020	SELL	$32.75 - $41.43 $4,978 - $6,297	-152 Reduced 0.04%	404,313 $13.9 Million
Q3 2019 Nov 13, 2019	BUY	$33.73 - $46.27 $13.2 Million - $18 Million	389,886 Added 2674.3%	404,465 $13.6 Million
Q2 2019 Aug 12, 2019	BUY	$29.6 - $40.93 $180,412 - $249,468	6,095 Added 71.84%	14,579 $597,000
Q1 2019 May 10, 2019	SELL	$27.85 - $38.09 $157,547 - $215,475	-5,657 Reduced 40.0%	8,484 $264,000
Q4 2018 Feb 14, 2019	SELL	$32.39 - $42.05 $63,613 - $82,586	-1,964 Reduced 12.19%	14,141 $512,000
Q3 2018 Nov 14, 2018	BUY	$35.69 - $47.65 $82,301 - $109,880	2,306 Added 16.71%	16,105 $628,000
Q2 2018 Aug 13, 2018	BUY	$28.41 - $42.41 $152,419 - $227,529	5,365 Added 63.61%	13,799 $0
Q1 2018 May 14, 2018	BUY	$21.18 - $33.78 $178,632 - $284,900	8,434 New	8,434 $253,000
Q4 2017 Feb 13, 2018	SELL	$19.29 - $24.83 $169,559 - $218,255	-8,790 Closed	0 $0
Q3 2017 Nov 02, 2017	BUY	$19.61 - $23.35 $172,371 - $205,246	8,790	8,790 $201,000

Others Institutions Holding XNCR

# of Institutions

214

Shares Held

71.8M

Call Options Held

2.5K

Put Options Held

7.9K

View Full List

About Xencor Inc

Ticker XNCR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,698,100
Market Cap $1.05B
Description
Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal ...

More about XNCR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Principal Financial Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Principal Financial Group Inc with notifications on news.

Account

Principal Financial Group Inc Xencor Inc Transaction History